I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q1, the actual value is USD 87.12 M.
EPS: As of FY2025 Q1, the actual value is USD -0.23.
Segment Revenue
- Total Revenue: $87.1 million, a 42% increase year-over-year.
- Exome and Genome Test Revenue: $71.4 million, a 62% increase year-over-year.
Operational Metrics
- Adjusted Net Income: $7.7 million compared to an adjusted net loss of $8.0 million in the first quarter of 2024.
- GAAP Net Loss: $6.5 million.
- Adjusted Gross Margin: 69%, compared to 61% in the first quarter of 2024.
- Total GAAP Gross Margin: 67%.
- Adjusted Total Operating Expenses: $52.3 million, or 60% of revenues, compared to 74% in the first quarter of 2024.
Cash Flow
- Cash Position: $160.2 million as of March 31, 2025.
- Cash Generated from Operations: $4.1 million.
- Proceeds from Stock Issuance: $13.9 million.
Unique Metrics
- Exome and Genome Test Volume: 20,562, a 24% increase year-over-year.
- Planned Acquisition: GeneDx announced plans to acquire Fabric Genomics, with the transaction expected to close in Q2 2025.
Outlook / Guidance
- GeneDx raised its full year 2025 revenue guidance to between $360 and $375 million, inclusive of $3 to $5 million from the planned acquisition of Fabric Genomics.
- The company expects growth in exome/genome volume and revenue of at least 30% and adjusted gross margins between 66%-68%.
- GeneDx anticipates profitability with adjusted net income each quarter and for the full year 2025.